Retatrutide vs Tirzepatide vs Semaglutide: Receptor Coverage Compared

Semaglutide, tirzepatide and retatrutide are distinguished in the published literature primarily by how many metabolic receptors each molecule engages: one, two, or three. Semaglutide is a single glucagon-like peptide-1 (GLP-1) receptor agonist; tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors; retatrutide is described as a triple agonist adding the glucagon receptor. This article compares them on receptor coverage, molecular size and the analytical consequences of that size. It is written in third person for a laboratory-research audience.

For research use only — not for human or veterinary use. Nothing below is medical, dosing or treatment advice, and no comparison of therapeutic effect is offered or implied.

Regulatory status in Australia comes first

Two of the three compounds named here correspond to registered prescription medicines in Australia, and that fact frames everything else.

• Semaglutide is a Schedule 4 (Prescription Only Medicine) substance under the Poisons Standard, and semaglutide-containing products are registered on the Australian Register of Therapeutic Goods. It is lawfully supplied in Australia for human use only on the order of an authorised prescriber.
• Tirzepatide likewise corresponds to a registered, prescription-only medicine in Australia; the TGA has published safety communications covering both GLP-1 and dual GIP/GLP-1 receptor agonist medicines.
• Retatrutide has no registered medicine in Australia. In the published literature it is an investigational molecule in ongoing clinical evaluation.

Research-grade reference material supplied for laboratory work is a different category of product from a registered medicine, and the two should not be conflated. Scheduling and registration change over time, and obligations differ by state and territory — the peptide regulations in Australia page explains how to check a compound's current status yourself rather than relying on any supplier's summary.

What each receptor does mechanistically

All three targets are class B1 G-protein-coupled receptors that signal predominantly through Gαs and adenylate cyclase, raising intracellular cAMP. What differs is where each receptor is expressed and what the native ligand does there.

The GLP-1 receptor (GLP1R)

UniProt catalogues the human GLP-1 receptor as a receptor for the gut-derived incretin glucagon-like peptide-1. In the mechanistic literature its activation is associated with glucose-dependent insulin secretion from pancreatic beta cells, slowed gastric emptying, and signalling in central and peripheral circuits that regulate food intake. It is the most extensively characterised of the three targets.

The GIP receptor (GIPR)

GIP is the second principal human incretin. Its receptor is expressed in pancreatic islets, adipose tissue and regions of the central nervous system studied in relation to energy balance. Because GIP and GLP-1 arrive from the same nutrient stimulus but act on partly non-overlapping tissues, combined agonism at both receptors has been investigated as mechanistically distinct from agonism at either alone.

The glucagon receptor (GCGR)

The glucagon receptor is expressed most prominently in liver and kidney. Preclinical work has examined glucagon signalling in relation to hepatic glucose output, lipid handling and energy expenditure — an axis that sits outside incretin biology altogether. Adding glucagon-receptor activity to a dual incretin agonist is the design change that defines a triple agonist.

Single, dual and triple agonism side by side

• Semaglutide — GLP-1 only. One receptor, one pathway.
• Tirzepatide — GIP and GLP-1. Two incretin receptors in a single molecule.
• Retatrutide — GIP, GLP-1 and glucagon. Two incretin receptors plus a non-incretin metabolic receptor.

Receptor coverage is not the same as potency at each receptor, and the two are frequently confused. A 2025 review in Biomolecules reports cell-based potency values for retatrutide of EC50 0.0643 nM at the human GIP receptor, 0.775 nM at the GLP-1 receptor and 5.79 nM at the glucagon receptor — that is, roughly a ninety-fold spread across the three targets it engages. A molecule can therefore be accurately described as a triple agonist while being far more potent at one of its three receptors than the others. Any comparison that treats "triple" as simply "more" ignores that spread.

Molecular size and structure

These are large, chemically modified peptides rather than small molecules, and the size differences are substantial.

• Semaglutide — PubChem lists molecular formula C187H291N45O59 and an average molecular weight of approximately 4,114 g/mol, built on a 31-residue GLP-1 analogue backbone with a C18 diacid side chain attached via a linker.
• Tirzepatide — PubChem lists C225H348N48O68 and an average molecular weight of approximately 4,813 g/mol, on a 39-residue backbone that also carries a fatty diacid moiety.
• Retatrutide — described in the literature as a synthetic peptide of comparable scale carrying a fatty diacid modification, adopting a single continuous helical structure that allows interaction with the transmembrane domains of more than one receptor family member.

For context, a small research peptide such as BPC-157 sits near 1,400 g/mol. The molecules in this class are three to four times that mass, with lipid modifications, non-natural residues and multiple ionisable groups. That has direct analytical consequences.

Why assay matters more in this class

On a Certificate of Analysis, purity is a composition figure — the proportion of ultraviolet-absorbing material that is the target peak on a reversed-phase HPLC trace. Assay is a quantity figure — the mass of target analyte the laboratory actually measured in the vial, compared against the label weight. They are independent measurements, and for large lipidated peptides the gap between them widens for several reasons.

• Counter-ions and residual moisture carry weight but no purity penalty. Acetate or trifluoroacetate counter-ions and adsorbed water contribute mass to a lyophilised cake without appearing as impurity peaks in a UV-normalised chromatogram. A vial can read 99.5% pure and still contain materially less target peptide than the label states.
• Closely related synthesis impurities co-elute. Deletion sequences and incompletely deprotected variants of a 39-residue lipopeptide differ from the target by a small fraction of total mass, and separating them demands a well-developed gradient. Identity confirmation by mass spectrometry is the check that catches what chromatography alone can miss.
• Concentration arithmetic depends on the assay, not the label. Reconstitution maths starts from the mass in the vial. If the measured assay differs materially from the printed label weight, every downstream concentration derived from that label is wrong by the same proportion. The reconstitution calculator does the arithmetic; only the certificate tells you which input to trust.

This is why, in a class of 4,000–5,000 g/mol modified peptides, a purity percentage on its own is a weak claim. The batch-specific reports in the TXLABS Certificate of Analysis library publish both figures — for example, a retatrutide lot assaying 29.97 mg against a 30 mg label weight at 99.762% purity, and a semaglutide lot assaying 11.85 mg against a 10 mg label at 99.471%.

What this comparison does not tell you

Receptor coverage, molecular weight and analytical figures describe what a molecule is. They say nothing about outcomes in people, and nothing here should be read as a comparison of therapeutic effect. The clinical literature on these compounds concerns registered or investigational medicines studied under regulated conditions — a separate matter from research-grade reference material supplied for laboratory characterisation.

Research-grade reference material for these compounds is listed in the metabolic and GLP-1 category, including semaglutide, tirzepatide and retatrutide. All materials are supplied For Research Use Only.

For research use only. Products supplied by TXLABS are laboratory research chemicals intended for in-vitro and laboratory research by qualified professionals. They are not medicines, supplements, foods or cosmetics, and are not for human or veterinary use.